Taysha Gene Therapies, Inc.
TSHA
$6.70
-$0.16-2.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -42.41M | -27.85M | -32.73M | -26.88M | -21.53M |
| Total Depreciation and Amortization | 295.00K | 299.00K | 286.00K | 277.00K | 283.00K |
| Total Amortization of Deferred Charges | -- | 0.00 | 147.00K | -- | -- |
| Total Other Non-Cash Items | 5.89M | 7.90M | 4.10M | 4.20M | 3.78M |
| Change in Net Operating Assets | -4.65M | -7.07M | 4.03M | 2.23M | -4.56M |
| Cash from Operations | -40.88M | -26.72M | -24.17M | -20.18M | -22.02M |
| Capital Expenditure | -24.00K | -250.00K | -108.00K | -2.00K | -378.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3.00M | 3.00K | 60.00K | 64.00K | 7.00K |
| Cash from Investing | -3.02M | -247.00K | -48.00K | 62.00K | -371.00K |
| Total Debt Issued | -- | 0.00 | 49.85M | -- | -- |
| Total Debt Repaid | -- | 0.00 | -40.61M | -- | -- |
| Issuance of Common Stock | 692.00K | 49.61M | -- | 216.17M | 75.00K |
| Repurchase of Common Stock | -- | -- | -173.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 19.00K | -57.00K | -271.00K | 118.00K | -127.00K |
| Cash from Financing | 711.00K | 49.56M | 8.80M | 216.29M | -52.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -43.19M | 22.59M | -15.42M | 196.17M | -22.44M |